Xuanzhu Biopharmaceutical Co., Ltd. (HKG:2575)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
10.56
-0.17 (-1.58%)
Aug 27, 2026, 4:08 PM HKT

Xuanzhu Biopharmaceutical Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2021FY 2020
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '21 Dec '20
Revenue
103.3251.7730.090.03--
Revenue Growth
99.57%72.03%103672.41%---
Gross Profit
30.8425.7214.71-2.17--
Operating Income
-201.64-233.41-563.78-339.31-416.96-238.69
Net Income
-209.94-245.51-556.43-300.56-461.58-162.45
Earnings Per Share
-0.42-0.53-1.23-0.67-1.17-
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2021FY 2020
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '21 Dec '20
Cash & Investments
508.47652.27246.02449.81,233958.02
Total Debt
0.220.651.4817.0729.360.04
Net Cash (Debt)
508.25651.62244.54432.731,204957.98
Net Cash Growth
-22.00%166.47%-43.49%-64.06%25.68%746.80%
Net Cash Per Share
1.031.400.540.963.05-

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2021FY 2020
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '21 Dec '20
Operating Cash Flow
--209.96-127.09-115.95-411.43-207.65
Capital Expenditures
--0.57-0.51-1.74-75.99-57.26
Free Cash Flow
--210.54-127.6-117.69-487.42-264.9
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2021FY 2020
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '21 Dec '20
Gross Margin
29.85%49.67%48.88%---
Operating Margin
-195.16%-450.85%-1873.40%-1170020.69%--
Pretax Margin
-203.19%-474.20%-1848.95%-1036400.00%--
Profit Margin
-203.19%-474.21%-1848.97%-1036420.69%--
FCF Margin
--406.66%-424.00%-405831.03%--

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2021FY 2020
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '21 Dec '20
PS Ratio
46.59633.81----